Skip to main content

Table 2 Association between patient-, tumor-, and therapy-related characteristics and Grade ≥ 2 radiation pneumonitis (N = 169)

From: Impact of genetic variant of HIPK2 on the risk of severe radiation pneumonitis in lung cancer patients treated with radiation therapy

ParameterUnivariable AnalysisMultivariable Analysis
HR95% CIPHR95% CIP
Sex
 Female1  1  
 Male1.2160.773–1.9150.3981.3790.758–2.5110.292
Age, years
  < 581  1  
  ≥ 581.4130.951–2.0980.0871.5410.997–2.3830.052
Histology
 SCLC1  1  
 NSCLC1.1950.791–1.8040.3981.2510.727–2.1530.418
Stage
 I-II1  1  
 III-IV1.1000.601–2.0130.7581.1320.593–2.1630.707
KPS
 80–1001  1  
  < 801.3410.877–2.0520.1761.5660.993–2.4700.054
Smoking
 Smoker1  1  
 Nonsmoker0.9260.619–1.3860.7080.9640.337–2.1920.435
Surgery
 Yes1  1  
 No1.0140.684–1.5040.9450.6900.390–1.2230.204
Chemotherapy
 Yes11 1  
 No0.5000.203–1.2330.1320.4730.189–1.1870.111
CRT
 Yes1  1  
 No0.8430.529–1.3440.4720.9560.575–1.5880.861
IMRT
 Yes1  1  
 No1.0770.726–1.5980.7121.0980.710–1.6990.675
Radiation dose, cGy
 <56001  1  
  ≥ 56001.0830.729–1.6100.6921.1390.633–2.5350.737
MLD, cGy
  < 15001  1  
  ≥ 15001.5101.093–2.2350.0451.8881.186–3.0040.007
V20
  < 24%1  1  
  ≥ 24%1.7301.138–2.6310.0102.1261.338–3.3780.001
COPD
 Yes1  1  
 No0.6390.246–1.6610.3580.7800.339–1.9980.472
  1. Note: Multivariable analyses were adjusted for all of the factors in this table, statistically significant p values for multivariable analysis were shown in boldface.
  2. *Either MLD or V20 was used in the multivariable analyses, but not both